Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

Biao Zheng, Yongxian Hu, Jiqin Zhang, Mingming Zhang, Wei Li, Wenjun Wu, Jiazhen Cui, Guoqing Wei, Bing Du, Mingyao Liu, He Huang

Blood (2023) 142 (Supplement 1): 2108.

https://doi.org/10.1182/blood-2023-185573

Published: 2023

Journal Articles

Characteristics of Central Nervous System Relapse after CD19 CAR-T Cell Therapy in R/R NHL

Mengyu Zhao, Tingting Yang, Yetian Dong, Wenxiao Li, Tianning Gu, Linghui Zhou, Jiazhen Cui, Wenfa Huang, Mingming Zhang, Lei Wang, Lixin Wang, Delin Kong, He Huang, Yongxian HU

Blood (2023) 142 (Supplement 1): 6915.

https://doi.org/10.1182/blood-2023-187951

Published: 2023

Journal Articles

Establishment of a Dynamic Ctdna Monitoring System to Predict the Prognosis of CAR-T Cell Therapy in R/R B-NHL Patients

Linghui Zhou, Tao Cheng, Yongxian HU, He Huang

Blood (2023) 142 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2023-179694

Published: 2023

Journal Articles

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

Blood (2023) 142 (Supplement 1): 1039.

https://doi.org/10.1182/blood-2023-185697

Published: 2023

Journal Articles

A Multicenter Study of CAR-T Cell Therapy for Relapse of B-ALL Post Allogeneic Stem Cell Transplantation

Jingjing Feng, He Huang, Yongxian HU

Blood (2023) 142 (Supplement 1): 3485.

https://doi.org/10.1182/blood-2023-184740

Published: 2023

Journal Articles

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Mingming Zhang, Yongxian Hu, Guoqing Wei, Shan Fu, Jingjing Feng, Ruimin Hong, Alex H. Chang, He Huang

Blood (2023) 142 (Supplement 1): 891.

https://doi.org/10.1182/blood-2023-186225

Published: 2023

Journal Articles

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

Yongxian HU, Guoqing Wei, Shan Fu, Pingnan Xiao, Jingjing Feng, Mingming Zhang, Xingbing Wang, Dongrui Wang, Jun Li, He Huang

Blood (2023) 142 (Supplement 1): 2111.

https://doi.org/10.1182/blood-2023-189052

Published: 2023

Journal Articles

CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study

Jingjing Feng, Yongxian HU, Alex H. Chang, He Huang

Blood (2023) 142 (Supplement 1): 4835.

https://doi.org/10.1182/blood-2023-186669

Published: 2023

Journal Articles

A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

Blood (2023) 142 (Supplement 1): 101.

https://doi.org/10.1182/blood-2023-185236

Published: 2023

Journal Articles

Genomic and Transcriptomic Profiling Reveal the Mechanism and Risk Factors of CD19-Negative Relapse after CAR-T Cell Therapy

Ruimin Hong, Linghui Zhou, Ye Meng, Mingming Zhang, Houli Zhao, Jiazhen Cui, Simao Huang, Yongxian Hu, He Huang

Blood (2022) 140 (Supplement 1): 6354–6355.

https://doi.org/10.1182/blood-2022-164955

Published: 2022

Journal Articles

MEK Inhibition in CAR-T Cells Prevents Exhaustion and Terminal Differentiation Via Downregulating C-Fos and JunB

Blood (2022) 140 (Supplement 1): 626–627.

https://doi.org/10.1182/blood-2022-158646

Published: 2022

Journal Articles

Central Nervous System Relapse after CAR-T Cell Therapy in B-Cell Malignancies

Tianning Gu, Wenfa Huang, Lei Wang, Yuqi Li, Lixin Wang, Yongxian Hu, He Huang

Blood (2022) 140 (Supplement 1): 13220–13221.

https://doi.org/10.1182/blood-2022-168477

Published: 2022

Journal Articles

Muticenter Retrospective Comparable Study of Prophylactic Versus Preemptive Modified Donor Lymphocyte Infusion for Patients with High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Luxin Yang, Xiaoyu Lai, Ting Yang, Ying Lu, Lizhen Liu, Jimin Shi, Yanmin Zhao, Yibo Wu, Yi Chen, Jian Yu, Haowen Xiao, Guifang Ouyang, Jinhua Ren, Junjie Cao, Yongxian Hu, Yamin Tan, Zhen Cai, He Huang, Yi Luo

Blood (2022) 140 (Supplement 1): 7676–7677.

https://doi.org/10.1182/blood-2022-166759

Published: 2022

Journal Articles

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia

Yiyun Wang, Linqin Wang, Mi Shao, Xiangjun He, Yanan Yue, Yixuan Zhou, Luhan Yang, He Huang, Yongxian Hu

Blood (2022) 140 (Supplement 1): 12685.

https://doi.org/10.1182/blood-2022-166420

Published: 2022

Journal Articles

High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study

Yongxian Hu, Jiqin Zhang, Mingming Zhang, Wei Li, Wenjun Wu, Jiazhen Cui, Guoqing Wei, Bing Du, Mingyao Liu, He Huang

Blood (2022) 140 (Supplement 1): 7491–7492.

https://doi.org/10.1182/blood-2022-156137

Published: 2022

Journal Articles

Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

Jingjing Feng, Yongxian Hu, Mingming Zhang, Heng Cao, Yini Ke, Huijun Xu, Jiazhen Cui, Yanlei Zhang, Alex Hongsheng Chang, Jin Lin, Guoqing Wei, He Huang

Blood (2022) 140 (Supplement 1): 10335–10336.

https://doi.org/10.1182/blood-2022-169265

Published: 2022

Journal Articles

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Blood (2022) 139 (23): 3376–3386.

https://doi.org/10.1182/blood.2021013733

Published: 2022

Includes: Supplemental data

Journal Articles

Predictive Value of Next-Generation Sequencing-Based Minimal Residual Disease after CAR-T Cell Therapy

Yue Huang, Houli Zhao, Mi Shao, Linghui Zhou, Guoqing Wei, Wenjun Wu, Alex Hong Chang, Tao Sun, Yongxian HU, He Huang

Blood (2021) 138 (Supplement 1): 2842.

https://doi.org/10.1182/blood-2021-149928

Published: 2021

Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 547.

https://doi.org/10.1182/blood-2021-152576

Published: 2021

Journal Articles

Venetoclax-Ponatinib for T315I/Compound-Mutated Ph+Acute Lymphoblastic Leukemia

Huafeng Wang, Jiejing Qian, Chang Yang, Yi Zhang, Yungui Wang, Ting Shi, Yongxian HU, Liping Mao, Xiujin Ye, Fang Liu, Zhenfang Xi, Lihong Shou, Caiyun Fu, Hua Naranmandura, Jie Jin, Hong-Hu Zhu

Blood (2021) 138 (Supplement 1): 3395.

https://doi.org/10.1182/blood-2021-152836

Published: 2021

NARROW

Long Term Follow-up Results of Brl-201 Phase I Study, a Crispr-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma

Characteristics of Central Nervous System Relapse after CD19 CAR-T Cell Therapy in R/R NHL

Establishment of a Dynamic Ctdna Monitoring System to Predict the Prognosis of CAR-T Cell Therapy in R/R B-NHL Patients

Neither Conditioning Chemotherapy Nor GvHD-Prophylaxis: CD7 CAR-T Treatment Bridging to Haplo-HSCT

A Multicenter Study of CAR-T Cell Therapy for Relapse of B-ALL Post Allogeneic Stem Cell Transplantation

Dasatinib and CAR-T Cell Therapy for Newly Diagnosed Ph-Positive Acute Lymphoblastic Leukemia in Adults

Intracellular Retention of Tcrαβ/CD3 to Generate Novel Allogeneic CAR-T Cells (ThisCART19A) with Enhanced Antitumor Potency for Treating B-ALL

CD19/BCMA CAR-T Cell Therapy for Refractory Systemic Lupus Erythematosus - Safety and Preliminary Efficacy Data from a Phase I Clinical Study

A Multi-Omic Single-Cell Landscape of Cytokine Release Syndrome in Multiple Myeloma Patients after Anti-BCMA CAR-T Cell Therapy

Genomic and Transcriptomic Profiling Reveal the Mechanism and Risk Factors of CD19-Negative Relapse after CAR-T Cell Therapy

MEK Inhibition in CAR-T Cells Prevents Exhaustion and Terminal Differentiation Via Downregulating C-Fos and JunB

Central Nervous System Relapse after CAR-T Cell Therapy in B-Cell Malignancies

Muticenter Retrospective Comparable Study of Prophylactic Versus Preemptive Modified Donor Lymphocyte Infusion for Patients with High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Off-the-Shelf, Multiplexed-Engineered iPSC-Derived CD33 CAR-NK Cells for Treatment of Acute Myeloid Leukemia

High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study

Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

Efficacy and safety of CD19-specific CAR T cell–based therapy in B-cell acute lymphoblastic leukemia patients with CNSL

Predictive Value of Next-Generation Sequencing-Based Minimal Residual Disease after CAR-T Cell Therapy

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Venetoclax-Ponatinib for T315I/Compound-Mutated Ph+Acute Lymphoblastic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only